MedTrace Logo

Efficacy and Safety of BGG492 in the Treatment of Migraine

NCT00892203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2020-12-17

No results posted yet for this study

Summary

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

Conditions

Interventions

DRUG

BGG492

DRUG

Sumatriptan

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Investigator Site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892203 on ClinicalTrials.gov